NxThera develops medical technologies to treat a variety of endourology conditions, including BPH.
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 3, 2015 | Series D | $40M | 1 | Boston Scientific | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Boston Scientific | Yes | Series D |